• Upstream Bio outlined Phase 3 plans for verekitug in severe asthma, chronic rhinosinusitis with nasal polyps, targeting single quarterly at-home injection dosing.
• FDA engagement slated for mid-2026; Phase 3 trials in severe asthma, chronic rhinosinusitis with nasal polyps targeted to start in Q1 2027.
• Phase 2 severe asthma data highlighted 56% reduction in annualized asthma exacerbation rate versus placebo for 100 mg every 12 weeks; lung function improved 122 mL; FeNO fell 20.4 ppb.
• Phase 2 chronic rhinosinusitis with nasal polyps data showed nasal polyp score reduction of 1.8 versus placebo; nasal congestion score improved 0.8; need for surgery or systemic steroids reduced 76%.
• Phase 2 COPD trial VENTURE enrollment capped; data expected in H2 2027; existing capital expected to fund planned operations through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.